Although the implication of inflammasome modulators in chronically inflamed LG remains unknown, their therapeutic potential is supported by our observation that the inhibition of Panx1 or Casp4 reduced the inflammation of LGs from thrombospondin-1-null (TSP-1-/-) mice, a model for SS, and improved the epithelium repair through the increased engraftment of progenitor cells [14]. This evidence concerns the gene THBS1 and synovial sarcoma.